iiinova — where your digital self keeps evolving

Reposted by Akshaya Jayachandran

Indian Society of Nephrology @isn-india.bsky.social · 12/09/2026

Peritoneal Dialysis explained in #Tamil. Kidney Konversations Podcast episode 19A on Spotify, ApplePodcasts and Amazonmusic with Dr Akshaya Jayachandran and Dr Sampath Kumar Check out these links 👉 open.spotify.com/episode/2xPc... podcasts.apple.com/in/podcast/k... @nephromommy-akshu.bsky.social

011

Reposted by Akshaya Jayachandran

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 10/07/2026

compare this with the almost flat GFR slope from interim telitacicept data (while we await atacicept aka Trutakna data) www.nephjc.com/news/2026/sh... from @nephromommy-akshu.bsky.social

041

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 04/05/2026

👂So, did you hear the one about avacopan and data manipulation? 🧮🧮🧮 @hswapnil.medsky.social has added onto our ADVOCATE summary with a "postscript" review of the controversies. #NephSky #MedSky www.nephjc.com/news/advocate?rq=avacopan

nephjc.com

Advocating for Patients with Vasculitis: A Steroid-Sparing Regimen with Avacopan — NephJC

This week, we will discuss the ADVOCATE trial. Avacopan is not just a flash in the pan? We hope so, having won the RheumMadness and offering a steroid free hope.

076

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 05/05/2026

Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs

nephjc.com

Is TRPC6 inhibition for FSGS a trick or a treat? — NephJC

This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterog...

0108

Reposted by Akshaya Jayachandran

kireports.bsky.social @kireports.bsky.social · 14/04/2026

1/ Hey #NephSky! 👋 We’re back with a fresh #Skytorial by @nephromommy-akshu.bsky.social We spend half our lives worrying about how bad creatinine is.. then keep using it anyway. What if we could measure bedside GFR - no serial blood samples? Let’s talk transdermal GFR (tGFR). @theisn.org

154

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 20/03/2026

#NephJC The #TenPostNephJC on REACT injections in DKD is live !! Missed the chat? Need a short recap of the study ? We’ve got you covered !! 😃

010

Reposted by Akshaya Jayachandran

KDIGO @kdigo.org · 18/03/2026

Are you attending the @theisn.org WCN 2026? Don’t miss the KDIGO activities at this year’s congress. See the flyers for key details, and be sure to visit KDIGO at booth #26. Learn more about the KDIGO GEM Satellite Symposium: kdigo.co/WCN26-GEM #ISNWCN program: www.theisn.org/wcn/program-...

043

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 11/03/2026

Everything said and done, once it reaches clinical practice - implementation is going to be pretty hard, coz the already established treatments are much simpler. And getting a patient to agree to an invasive procedure like a renal biopsy is gonna be next to impossible ! #NephJC

221

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 09/03/2026

We're discussing 💉REACT- renal autologous cell treatments (rilprencel) in diabetic kidney disease. Is regenerative medicine the future of nephrology❓ Come discuss 3/10/26 at 9pm #NephJC #NephSky Blog by @drsaivani.bsky.social and @nephromommy-akshu.bsky.social www.nephjc.com/news/rilprencel-react

nephjc.com

Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease? — NephJC

This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.

0128

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 11/03/2026

Hey #NephJC I’m Akshaya J, from Vellore India - glad to be here ! Currently, we’re not able to construct the DKD Building coz most of our patients can’t afford the 4 pillars of DKD!! 2 pillars are our usual practice 😅 !! 5th pillar ? Seems like a fantasy 😇 !! WKD2026 going full throttle at CMC !

051

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 25/02/2026

What is the group’s experience on Oral Iron + continuing ESAs while TSAT < 20%. Definitely not ideal, still I would like to know. Or traditional IV formulations like Iron Sucrose? #NephJC

010

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 25/02/2026

Hey all, This is Akshaya, junior Nephrologist from India, #NephJC intern and aggressive HIF-PHI prescriber !! Got late, despite the multiple reminders ⏰ on my phone !! Apologies!

150

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 11/02/2026

✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award 👇Here's a reminder of previous winners 📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form www.nephjc.com/news/... #NephJC

0115

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 11/02/2026

T -15min 👉Before we start, a few reminders! Are you new to #NephJC? Not sure what to do or how this works? Here is a quick rundown, an infographic made by Sinead Stoneman

031

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 11/02/2026

⏰30 min before the #NephJC chat There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC Are you pumped to know how and how well #Flozins work in transplanted patients? Let's deep dive in a few minutes!

074

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 11/02/2026

⏰2 hours until #NephJC chat SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat. 1/2

162

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 08/02/2026

Hey #NephSky 2/10/26 at 9 pm EST we'll discuss #Flozinating into the Future & Beyond... SGLT2i in kidney transplant recipients. What's the latest evidence of risk/benefit? Do #Flozins act mechanistically the same in de-innervated kidneys? Come chat. www.nephjc.com/news/inifinti-flozins-transplant

nephjc.com

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

099

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 28/01/2026

Potassium sits at the center of physician anxiety 😟 Tonight, we ask a provocative question with POTCAST 👉 Are we really targeting the “correct” potassium range? #NephJC

162

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 26/01/2026

Oh, the weather outside is frightful 🥶🥶 But #NephJC is so delightful, and since you've no place to go #NephSky... Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky Summary by @shelliefravel.bsky.social @salinesolut.bsky.social www.nephjc.com/news/potcast

nephjc.com

POTCAST- K+ Pop and Arrhythmia Drop — NephJC

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

2139

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 16/01/2026

6/10 Give me something clever to say 🤓 @nephromommy-akshu.bsky.social bsky.app/profile/neph...

151

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 14/01/2026

🎨Beautiful visual abstract by Dr Akshaya Akshaya Jayachandran #NephJC

172

Reposted by Akshaya Jayachandran

Sayali Thakare @sayalibthakare.bsky.social · 14/01/2026

Hey #NephJC friends! Sayali here, from Mumbai! Perplexed and vexed by this disease. Waiting for a cure, & more importantly, waiting for the cure to be shipped to India! Good job on the abstract @nephromommy-akshu.bsky.social & summary @drsaivani.bsky.social ! 👍🏻

021

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 14/01/2026

T0b The pathophysiology of C3GN & IC-MPGN is thought to be caused by: Genetic mutations or Acquired defect of complement proteins or Auto-antibodies against complement factors and/or regulating proteins. #NephJC

182

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 14/01/2026

⏰2 hours until #NephJC chat Join us today to learn more about the recently released VALIANT study, which investigates the use of Pegcetacoplan in C3 glomerulonephropathy and immune complex mediated glomerulonephritis

053

Reposted by Akshaya Jayachandran

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 13/01/2026

We will be discussing C3G today - so review the disease and the journey so far with Prof Carla Nester: youtu.be/Fo6J__RgWA0?... From our #NephGR a few months ago Excellent crisp overview of the science!

youtu.be

C3 Glomerulopathy: The Promise of a targeted therapy with Prof. Carla Nester

YouTube video by Ottawa Nephrology

0124

Reposted by Akshaya Jayachandran

Milagros Flores @dramiliflores.bsky.social · 13/01/2026

🧬 C3G APPEAR-C3G or VALIANT? 📉 Proteinuria vs placebo: 🔹 Iptacopan: 35% 🔹 Pegcetacoplan: 67% 🎯 Blocking factor B 🆚 🚫C3 Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org 🦋 join us today on #nephjc

077

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 15/12/2025

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

nephjc.com

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D — NephJC

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

21212

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 03/12/2025

T3d Benefits may vary, and results in the general population on CV risk and mortality are still controversial. Overall, the results of recent studies have been mixed results. Different study populations, end points and dosing may account for the lack of clarity. #NephJC

195

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 03/12/2025

Hey this is Akshaya, junior faculty from CMC Vellore, India. Currently joining in from Taiwan 🇹🇼 - here for the APCN ! 🐟 Honestly, most of my CKD patients are poor and I’ve been guilty of stopping some of their randomly prescribed fish oil because it costed them a whale! #NephJC

Some fish I found at Taipei Airport yesterday !
Yeah I’ve been seeing fish everyday after working on the PISCES summary !

470

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 01/12/2025

Holy Mackerel! 🐟 🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST Check out the PISCES VA by @brianrifkin.bsky.social www.nephjc.com/news/piscesva

nephjc.com

PISCES: The Visual Abstract — NephJC

Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

01411

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 19/11/2025

⏰ 2 hours until chat tonight #NephJC editorial team debated for a long time...not whether to discuss @kdigo.org IgAN guidelines, but whether to do it after #Kidneywk...Have we said it well: IgAN guidelines: fresh out of press, already aging gracefully? 👀See it for yourself

nephjc.com

2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC

This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

024

Reposted by Akshaya Jayachandran

ISNkidneycare @theisn.org · 10/11/2025

TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by @nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.

121

Reposted by Akshaya Jayachandran

Michelle Rheault, MD @rheaultm.bsky.social · 06/11/2025

Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself) Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵

35022

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 28/10/2025

Wonderful ! 😇 A patient’s perspective on IgA Nephropathy ! #NephJC #Nephsky #MedSky

050

Akshaya Jayachandran @nephromommy-akshu.bsky.social · 15/10/2025

Hey this is Akshaya, nephrologist from India! We’ve traditionally been restricting protein to our CKD patients until they go on to require dialysis ! A lot of our practices are changing nowadays though. Would love to get some good-y food-y insights from this chat ! #NephJC

050

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 13/10/2025

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR? www.nephjc.com/news/2025/10...

nephjc.com

Protein supplementation in CKD: The Visual Abstract — NephJC

We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?

01313

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 06/10/2025

Up next! CKD & Protein: Is Your Diet a Solution or a Silent Stressor? 🥩🔍 On October 14, we're discussing protein diets and outcomes in CKD/ESRD which still remains an enigma. ☀️📚 #NephJC pubmed.ncbi.nlm.nih.gov/40876553/ #Skytorial by @nephromommy-akshu.bsky.social Akshaya's signing off 👋

A Skit we performed for Women In Nephrology (WIN-ICON) India conference at Chennai in Sep 2025.

066

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 06/10/2025

10/10 Final #NephJC thoughts 🤔💭 While the study was a success, it is still a harsh reality that there exist many barriers to even getting a transplant. Much work is needed to safely simplify the procedure and make being IS - free a reliable reality for all kidney transplant patients! #NephJC

123

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 06/10/2025

9/10 I want more info: 👓📖 Please go through the insightful summary by Akshaya Jayachandran @nephromommy-akshu.bsky.social and Natalia Nombera @roxnonna23.bsky.social 🔖📖 🎨Beautiful visual abstract by Bogdan @thekidneywhisperer.bsky.social #NephJC www.nephjc.com/news/chimera...

121

Reposted by Akshaya Jayachandran

Nephrology Journal Club @nephjc.bsky.social · 06/10/2025

8/10 #NephJC Quote of the fortnight from @brianrifkin.bsky.social 💬 Immune tolerance is nice, but unpredictable and requires constant vigilance to prevent rejection. Would modifying graft kidneys to make them less antigenic be a better bet? #NdphJC

121